IP Review

This fragment is available on index.html

This publication includes IP covered under the following statements.

ISO maintains the copyright on the country codes, and controls its use carefully. For further details see the ISO 3166 web page: https://www.iso.org/iso-3166-country-codes.html
Show Usage
- ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code : EHDSICountry and PatientMyHealthEu
Produced by HL7 under the terms of HL7® Governance and Operations Manual relating to Intellectual Property (Section 16), specifically its copyright, trademark and patent provisions. This document is licensed under Creative Commons "No Rights Reserved" (CC0).
Show Usage
- Absent and Unknown Data - IPS : EHDSIAbsentOrUnknownProblem
The UCUM codes, UCUM table (regardless of format), and UCUM Specification are copyright 1999-2009, Regenstrief Institute, Inc. and the Unified Codes for Units of Measures (UCUM) Organization. All rights reserved. https://ucum.org/trac/wiki/TermsOfUse
Show Usage
- Unified Code for Units of Measure (UCUM) : EHDSIUnit
These codes are excerpted from Digital Imaging and Communications in Medicine (DICOM) Standard, Part 16: Content Mapping Resource, Copyright Â© 2011 by the National Electrical Manufacturers Association.
Show Usage
- DICOM Controlled Terminology Definitions: EHDSIModality and EHDSITechnicalModality
This artifact includes content from International Standard Classification of Occupations (ISCO). ISCO is copyright International Labour Organization (ILO). Terms & Conditions in http://www.ilo.org/global/copyright/lang--en/index.htm
Show Usage
- International Standard Classification of Occupations (ISCO) : EHDSIHealthcareProfessionalRole and PractitionerRoleMyHealthEu
This material contains content from LOINC . LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license . LOINC® is a registered United States trademark of Regenstrief Institute, Inc.
Show Usage
- LOINC : CompositionIdrMyHealthEu , DiagnosticReportIdrMyHealthEu ... Show 4 more
This material contains content that is copyright of SNOMED International. Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information contact https://www.snomed.org/get-snomed or info@snomed.org .
Show Usage
- SNOMED Clinical Terms® (SNOMED CT®) : BodyStructureMyHealthEu , EHDSIAllergenNoDrug ... Show 16 more
This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html
Show Usage

hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )

((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol ( src )

((R)-7-((1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl)amino)-2-(6-methoxypyridin-2-yl)pyrazolo [1,5-a]pyrimidine-6-carboxamide) ( src )

((Trans)-4-((2-(((2-chloro-4-((((R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)carbamoyl)oxy)ethyl)(methyl)amino)cyclohexyl 2-hydroxy-2,2-di(thiophen-2-yl)acetate ( src )

(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate ( src )

(R)-(-)-N-(2-(3-((6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl)piperidino)ethyl)-4-fluorobenzamide ( src )

(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone ( src )

(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-hydroxy-6-methylpyridin-2-yl)methanone ( src )

(R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile ( src )

(R)-1-(1-Acryloylpiperidin-3-yl)-4-amino-N-(4-(2-(dimethylamino)-2-oxoethyl)-2,3-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide ( src )

(R)-1-(5-tert-butyl-indan-1-yl)-3-(1H-indazol-4-yl)-urea ( src )

(R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide ( src )

(R)-2-(4-(Cyclopropylsulfonyl)phenyl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide ( src )

(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-(1,2,4)triazolo(4,3-a)pyrimidin-5-yl)phenyl)-n,n,n-trimethylethanaminium methanesulfonate ( src )

(R)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-[11C]methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one ( src )

(R)-2-Amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-one ( src )

(R)-3,3,3-trifluoro-N-(2-fluoro-5-trifluoromethylbenzyl)-2-hydroxy-2-phenylpropanamide ( src )

(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea ( src )

(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea fumarate ( src )

(R)-3-(1-Cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide ( src )

(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione ( src )

(R)-3-Chloro-1,2-propanediol ( src )

(R)-4-((3-(1H-Imidazol-1-yl)-6,6-dimethylcyclohex-2-en-1-yl)(methyl)amino)-2-(trifluoromethyl)benzonitrile ( src )

(R)-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one ( src )

(R)-4-((5-(3-hydroxy-3-methyl-2-oxoindolin-1-yl)pyridin-3-yl)methyl)phthalazin-1(2H)-one mesilate ( src )

(R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol ( src )

(R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile ( src )

(R)-6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine ( src )

(R)-ALPHA-GLYCEROPHOSPHORYLETHANOLAMINE MONOHYDRATE ( src )

(R)-Bicalutamide ( src )

(R)-Deuteropioglitazone ( src )

(R)-Deuteropioglitazone hydrochloride ( src )

(R)-Glycidyl tosilate ( src )

(R)-Ketamine ( src )

(R)-Ketamine hydrochloride ( src )

(R)-Mequitazine ( src )

(R)-N-(1-(3-(Cyclopentyloxy)phenyl)ethyl)-3-((2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide ( src )

(R)-N-(1-carboxy-3-((phenylacetyl)amino)propyl)-L-leucyl-N,O-dimethyl-L-tyrosinamide ( src )

(R)-N-(3-(2-Chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide ( src )

(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide ( src )

(R)-Otenaproxesul ( src )

(R)-Styrene oxide ( src )

(R)-Warfarin ( src )

(R)-alpha-glycerophosphorylethanolamine ( src )

(R)-fadrozole phosphate ( src )

(R)-troloxamide quinone ( src )

(S)-4-(((R)-6-(2-Chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic acid ( src )

(r)-4-((4-(((4-(tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol ( src )

1-(4'-(3-methyl-4-(((((R)-1-phenylethyl)oxy)carbonyl)amino)isoxazol-5-yl)biphenyl-4-yl)cyclopropanecarboxylic acid ( src )

2-((R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide ( src )

3-((S)-4-(5-((4-(4-chlorothiophen-2-yl)-5-(((R)-2-methylpyrrolidin-1-yl)methyl)thiazol-2-yl)carbamoyl)pyrazin-2-yl)-2-methylpiperazin-1-yl)propanoic acid ( src )

4-[(5-bromo-4-{[(R)-1-hydroxypropan-2-yl]amino}pyrimidin-2-yl)amino]benzenesulfonamide ( src )

4-[4-[(R)-[2-(4-Chlorophenyl)phenyl]-hydroxymethyl]piperidin-1-yl]-N-[4-[[(2R)-4-[2-hydroxyethyl(methyl)amino]-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide ( src )

4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide ( src )

4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide sesquifumarate ( src )

5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one ( src )

9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine ( src )

ADENOSINE, (P(R))-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-P-THIOADENYLYL-(2'->5')-, CYCLIC NUCLEOTIDE ( src )

ADENOSINE, (P(R))-5'-O-((R)-HYDROXYMERCAPTOPHOSPHINYL)-P-THIOADENYLYL-(2'->5')-, CYCLIC NUCLEOTIDE, SODIUM SALT (1:2) ( src )

AMPHISOL® K ( src )

Archetype ID openEHR-EHR-CLUSTER.anatomical_location.v1 Concept name Anatomical Location Concept description Record details about an anatomical location. Keywords location, site, anatomical Copyright © openEHR Foundation Purpose To record details about anatomical location. Misuse Not for specifiying unilateral/bilateral occurrence - this is related to an evaluation which perhaps includes multiple locations. Author Author name: Heather Leslie Organization: Ocean Informatics Email: heather.leslie@oceaninformatics.com Date of Origination: 2008-11-10 Translator Norwegian Bokmål: Lars Bitsch-Larsen, Haukeland University Hospital of Bergen, Norway, MD, DEAA, MBA, spec in anesthesia, spec in tropical medicine. Arabic (Syria): Mona Saleh Other contributors Heather Leslie, Ocean Informatics, Australia (Editor) Ian McNicoll, freshEHR Clinical Informatics, United Kingdom (Editor) Dunmail Hodkinson, Black Pear Software Ltd, UK References Use cases: - 5LICS, midclavicular line - L forearm, 2cm anterior to the cubital fossa - Right iliac fossa - 5 cm below L tibial tuberosity - 2 cm medial to R nipple - 4 cm below R costal margin in midclavicular line - R femur - midline nose - medial aspect of R great toe nail. ( src )

Code of Federal Regulation 21CFR§1271.290(c) ( src )

Copyright/Legal: This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc ( src )

Copyright/Legal: This value set includes content from SNOMED CT, which is copyright © 2002+ International Health Terminology Standards Development Organisation (IHTSDO), and distributed by agreement between IHTSDO and HL7. Implementer use of SNOMED CT is not covered by this agreement ( src )

Methyl (R)-3-chloro-3'-fluoro-4'-(1-(1-(2,2,2-trifluoroacetamido)cyclopropane-1-carboxamido)ethyl)-[1,1'-biphenyl]-2-carboxylate ( src )

Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate ( src )

Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate ( src )

MyHealth@Eu Imaging Diagnostic Report - Local Development build (v0.0.1) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions ( src )

N-(2-hydroxyethyl)-2-((Z)-4,4,7-trifluoro-1-(4-((R)-2-fluoropropoxy)-2-(trifluoromethyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene)acetamide ( src )

N-Tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide ( src )

Produced by HL7 under the terms of HL7® Governance and Operations Manual relating to Intellectual Property (Section 16), specifically its copyright, trademark and patent provisions. This document is licensed under Creative Commons "No Rights Reserved" (CC0). Show Usage * Absent and Unknown Data - IPS: EHDSIAbsentOrUnknownProblem ( src )

Sodium (R)-2-(2-amino-3-(1H-indol-3- yl)propanamido)-2-methylpropanoate-propan-2-ol ( src )

TEKPRINT ® SB 1010 N RED2 ( src )

The Value Set is used to code clinical conditions relevant for the laboratory results interpretation. It is defined as the union of: (a) EHDSIIllnessandDisorder (b) EHDSIRareDisease (c) EHDSIReactionAllergy (d) EHDSIExceptionalValue ( src )

The Value Set is used to code the value of laboratory observation result. It is defined as the union of: (a) eHDSIBloodGroup (b) eHDSIPresenceAbsence (c) eHDSIMicroorganism (d) eHDSIExceptionalValue ( src )

These codes are excerpted from Digital Imaging and Communications in Medicine (DICOM) Standard, Part 16: Content Mapping Resource, Copyright Â© 2011 by the National Electrical Manufacturers Association. Show Usage * DICOM Controlled Terminology Definitions: EHDSIModality and EHDSITechnicalModality ( src )

This material contains content from LOINC. LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. Show Usage * LOINC: CompositionIdrMyHealthEu, DiagnosticReportIdrMyHealthEu... Show 4 more , EHDSIImagingCode, EHDSILabCode, EHDSILabStudyType and EHDSILaboratoryReportTypes ( src )

This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html Show Usage * Observation Category Codes: EHDSIObservationCategory * Observation Reference Range Meaning Codes: EHDSIReferenceRangeMeaning * Sex Parameter For Clinical Use: EHDSIReferenceRangeAppliesTo * NullFlavor: EHDSIExceptionalValue * ObservationInterpretation: EHDSIObservationInterpretation * ParticipationType: EHDSIPerformerFunction ( src )

External References

Unattributed Code Systems

Copyright Fragment

Copyright and Registered Trademark Uses

External References

Internal Images